Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scar treatment TRTP-101 tracked for Long-Term safety

NCT ID NCT06435884

Symptom relief Sponsor: CellinCells Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study checks the long-term safety and effectiveness of TRTP-101, a treatment for atrophic (depressed) scars. It follows 3 adults who already received TRTP-101 in an earlier study. Researchers will monitor serious side effects and measure changes in scar volume and patient satisfaction over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

3 people

The number who actually took part.

Started

Sep 2024

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with Atropic Scars Treated with TRTP-101 in Sutdy CIC101-01

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Received TRTP-101 in clinical trial CIC101-01 * Provided written informed consent to participate in this study Exclusion Criteria: * Judged to be unsuitable to participate in this long-term follow-up

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrophic scar are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrophic scar

Contacts and locations

Locations

  • Samsung Medical Center

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.